Tuesday, March 21, 2017

Today's Calls
1. Buy Panacea Biotech Ltd at Rs.155-156, T: Rs.170, SL: Rs.152.   Renowned cardiologist Dr
.Devi Shetty founded multi-speciality hospital chain Narayana Hrudayalaya is on the prowl to bolster its footprint in the domestic healthcare services market. ET NOW learns from multiple sources privy to ongoing discussions that the Bangalore, Karnataka headquartered firm is in advanced talks to buy out Delhi based drugmaker Panacea Biotec's multi super-speciality hospital located in Gurgaon, Harayana. 
On the other hand, Narayana Hrudalaya confirmed that the company has been in discussions with Panacea Biotec for Gurgaon Hospital since October 2015.
Giving the chronological order of the events, the company said in December 2016, it had signed a non-binding MoU with the counter party and in March this year, due diligence is under progress. The company  in January this year, got the US Food and Drug Administration’s (FDA) approval for Rizatripan Bonzoate tablet, which is used to treat symptoms due to migraine.

The company also entered a long term agreement with UNICEF for suplying Pentavalent vaccine.

2. Those who have entered UCO Bank should keep a strict SL of Rs.35.50 and keep holding. The banking sector is in mess, with Narendra Modi's government till date giving only lip service. That stock did not move much even lafter the announcement of infusion of capital raises further concerns regarding its health/asset quality. If you are not comfortable then exit at Rs.35.90-30, with no profit or with minimum loss near the recommended prices.

3. Those who are holding Tata Motors Ltd can continue to hold with a SL of Rs.466. Most of the brokerage houses are positive on the scrip. However, too much optimism make a stock over but owned, which is also not good.

4. The scrip of BHEL (Rs.169.40) was recommended in this blog around Rs.105-1 107 the scrip made a 52-week high today at Rs.172.10 in the NSE. The investors are suggested to book complete profits and wait on the sidelines, for entry at dips. When I recommended the stock many of the research houses and brokerages were extremely bearish, some were giving targets as low as Rs.70.

Post a Comment